AI Business
18h ago
Novo Nordisk Transfers Parkinson's Therapy to AI Startup Supported by Mark Zuckerberg
May 11, 2026
AI Summary
Novo Nordisk has transferred rights to an experimental Parkinson's disease therapy to the AI startup Cellular Intelligence, which is backed by Mark Zuckerberg. This partnership aims to accelerate the therapy's development through clinical trials, with Novo potentially earning milestone payments and royalties upon success.
- Novo Nordisk A/S has agreed to transfer an experimental therapy for Parkinson's disease to Cellular Intelligence, an AI startup supported by Mark Zuckerberg.
- Cellular Intelligence will manage the therapy's development and clinical trials.
- Novo Nordisk, known for its obesity treatment Wegovy, will receive milestone payments and royalties if the therapy is successful.
- As part of the agreement, Novo Nordisk will also acquire a stake in Cellular Intelligence.
- Financial details of the deal have not been disclosed.
parkinsonsstartuptherapeuticsinvestmentai